Syndax Pharmaceuticals Inc Quarterly Debt-to-equity in % from Q3 2016 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Syndax Pharmaceuticals Inc quarterly Debt-to-equity history and growth rate from Q3 2016 to Q2 2024.
  • Syndax Pharmaceuticals Inc Debt-to-equity for the quarter ending June 30, 2024 was 10.5 %, a 60.4% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 10.5 +3.94 +60.4% Jun 30, 2024
Q1 2024 10 +2.54 +33.9% Mar 31, 2024
Q4 2023 8.82 -0.48 -5.16% Dec 31, 2023
Q3 2023 7.55 -2.91 -27.8% Sep 30, 2023
Q2 2023 6.52 -6.43 -49.7% Jun 30, 2023
Q1 2023 7.5 -7.38 -49.6% Mar 31, 2023
Q4 2022 9.31 -8 -46.2% Dec 31, 2022
Q3 2022 10.5 -10.7 -50.5% Sep 30, 2022
Q2 2022 12.9 -10.7 -45.3% Jun 30, 2022
Q1 2022 14.9 -10.4 -41.2% Mar 31, 2022
Q4 2021 17.3 -15.6 -47.3% Dec 31, 2021
Q3 2021 21.1 -27.1 -56.2% Sep 30, 2021
Q2 2021 23.7 -34.5 -59.3% Jun 30, 2021
Q1 2021 25.3 -55 -68.5% Mar 31, 2021
Q4 2020 32.9 -30.9 -48.4% Dec 31, 2020
Q3 2020 48.2 -8.84 -15.5% Sep 30, 2020
Q2 2020 58.1 +5.91 +11.3% Jun 30, 2020
Q1 2020 80.3 +30 +59.6% Mar 31, 2020
Q4 2019 63.7 +16 +33.5% Dec 31, 2019
Q3 2019 57.1 +16.2 +39.7% Sep 30, 2019
Q2 2019 52.2 +16.3 +45.4% Jun 30, 2019
Q1 2019 50.3 +20.3 +67.9% Mar 31, 2019
Q4 2018 47.7 +18.8 +64.7% Dec 31, 2018
Q3 2018 40.8 +12.4 +43.8% Sep 30, 2018
Q2 2018 35.9 +8.36 +30.3% Jun 30, 2018
Q1 2018 30 +3.2 +12% Mar 31, 2018
Q4 2017 29 +5.68 +24.4% Dec 31, 2017
Q3 2017 28.4 -120 -80.8% Sep 30, 2017
Q2 2017 27.6 Jun 30, 2017
Q1 2017 26.8 Mar 31, 2017
Q4 2016 23.3 Dec 31, 2016
Q3 2016 148 Sep 30, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.